Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Lobbying filed by GSK (FKA GLAXOSMITHKLINE INC.)
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Lobbying filed by GSK (FKA GLAXOSMITHKLINE INC.)
Lobbying filed by AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Read twice and referred to the Committee on Foreign Relations.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $960.0M | Apr 22, 2024 | 2024Q1 | BUDCPTHCR |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $696.0M | Jul 22, 2024 | 2024Q2 | BUDCPTHCR |
Congress members who traded stocks in companies connected to lobbying on this bill, within 90 days of its introduction date.
| Member | Party | Ticker | Company | Trade | Date | Amount | Timing | Lobbying Client | Conflict |
|---|---|---|---|---|---|---|---|---|---|
| Robert P. Bresnahan, Jr. | R | K | K | Buy | Apr 8, 2025 | $1,001 - $15,000 | 28d after | GSK (FKA GLAXOSMITHKLINE INC.) | 37% |
| Gilbert Ray Cisneros, Jr. | D |
3 trades by 2 members of Congress in companies connected to lobbying on S 935. The average conflict score is 35%.
CapitolExposed identifies the "bill-lobbying-trade pipeline" by: (1) finding lobbying filings (LD-2) that specifically mention this bill, (2) matching lobbying clients to publicly traded companies, and (3) finding stock trades by members of Congress in those companies within 90 days of the bill's introduction date. Trades made before the bill was introduced are highlighted in red, as they may indicate advance knowledge. This analysis surfaces correlations worthy of scrutiny; it does not prove wrongdoing.
Gilbert Ray Cisneros, Jr. bought K
Bill introduced
Robert P. Bresnahan, Jr. bought K
Gilbert Ray Cisneros, Jr. bought K
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $151.0M | Jul 22, 2024 | 2024Q2 | BUDCPTHCR |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | $106.0M | Oct 18, 2024 | 2024Q3 | HCRMEDMMM |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $82.0M | Apr 22, 2024 | 2024Q1 | BUDCPTHCR |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | $70.0M | Apr 18, 2024 | 2024Q1 | HCRMEDMMM |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | $54.0M | Jul 19, 2024 | 2024Q2 | HCRMEDMMM |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | $49.0M | Jan 17, 2025 | 2024Q4 | HCRMEDMMM |
| MEHLMAN CONSULTING, INC. | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | $8.0M | Jan 21, 2025 | 2024Q4 | MMMPHACPT |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | NATIONAL MULTIPLE SCLEROSIS SOCIETY | $7.4M | Apr 22, 2024 | 2024Q1 | BUDHCRMMM |
| HUMAN RIGHTS FIRST | HUMAN RIGHTS FIRST | $6.7M | Apr 21, 2025 | 2025Q1 | IMMFORCIV |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | NATIONAL MULTIPLE SCLEROSIS SOCIETY | $6.1M | Oct 16, 2024 | 2024Q3 | BUDHCRMMM |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | NATIONAL MULTIPLE SCLEROSIS SOCIETY | $5.1M | Jan 21, 2025 | 2024Q4 | BUDHCRMMM |
| MEHLMAN CONSULTING, INC. | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | $5.0M | Oct 18, 2024 | 2024Q3 | MMMPHACPT |
| MEHLMAN CONSULTING, INC. | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | $5.0M | Jul 18, 2024 | 2024Q2 | CPTMMMPHA |
| MEHLMAN CONSULTING, INC. | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | $5.0M | Apr 19, 2024 | 2024Q1 | MMMPHACPT |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | NATIONAL MULTIPLE SCLEROSIS SOCIETY | $4.2M | Jul 18, 2024 | 2024Q2 | BUDHCRMMM |
| WHITMER & WORRALL, LLC | CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | $3.0M | Feb 3, 2025 | 2024Q4 | MMMCPTPHA |
| WHITMER & WORRALL, LLC | CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | $3.0M | Oct 17, 2024 | 2024Q3 | MMMCPTPHA |
| WHITMER & WORRALL, LLC | CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | $2.0M | Jul 18, 2024 | 2024Q2 | MMMCPTPHA |
| WHITMER & WORRALL, LLC | CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | $2.0M | May 7, 2024 | 2024Q1 | MMMCPTPHA |
| K |
| Buy |
| Jan 24, 2025 |
| $1,001 - $15,000 |
| 46d before |
| GSK (FKA GLAXOSMITHKLINE INC.) |
| 32% |
| Gilbert Ray Cisneros, Jr. | D | K | K | Buy | Apr 29, 2025 | $1,001 - $15,000 | 49d after | GSK (FKA GLAXOSMITHKLINE INC.) | 36% |